We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $8.17B
1-Year Est. Return 68.82%
This Fund
S&P 500
This Quarter Est. Return
+25.15%
1 Year Est. Return
+68.82%
3 Year Est. Return
+79.68%
5 Year Est. Return
+64.24%
10 Year Est. Return
+259.8%
AUM
$8.17B
AUM Growth
+$2.55B
Cap. Flow
+$12.3M
Cap. Flow %
0.15%
Top 10 Hldgs %
61.52%
Holding
432
New
171
Increased
73
Reduced
69
Closed
99

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$36.5M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$36.1M
3
SNY icon
Sanofi
SNY
+$34.1M
4
CYTK icon
Cytokinetics
CYTK
+$31.4M
5
WAT icon
Waters Corp
WAT
+$25.6M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$147M
2
PTCT icon
PTC Therapeutics
PTCT
+$72.4M
3
IMVT icon
Immunovant
IMVT
+$55.7M
4
DDOG icon
Datadog
DDOG
+$31.8M
5
AVNS
Avanos Medical
AVNS
+$28M

Sector Composition

Rank Sector Weight
1 Miscellaneous 55.89%
2 Healthcare 30.09%
3 Technology 6.58%
4 Consumer Discretionary 3.42%
5 Communication Services 1.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QGEN icon
401
Qiagen
QGEN
$8.98B
– –
-6,792
Closed -$272K
RDN icon
402
Radian Group
RDN
$4.85B
– –
-7,523
Closed -$249K
REVB icon
403
Revelation Biosciences
REVB
$4.02M
– –
-323,241
Closed -$388K
RITM icon
404
Rithm Capital
RITM
$5.63B
– –
-48,987
Closed -$464K
RIVN icon
405
Rivian
RIVN
$22.8B
– –
-10,007
Closed -$151K
RKDA icon
406
Arcadia Biosciences
RKDA
$1.14M
– –
-159,390
Closed -$220K
RKLB icon
407
Rocket Lab Corp
RKLB
$41.1B
– –
-3,571
Closed -$229K
RVPH
408
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
– –
-592,079
Closed -$432K
SCHW
409
Charles Schwab
SCHW
$189B
– –
-3,025
Closed -$284K
SCLX icon
410
Scilex Holding
SCLX
$38.1M
– –
-297,706
Closed -$1.98M
SGMO
411
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-40,400,067
Closed -$9.97M
TENX icon
412
Tenax Therapeutics
TENX
$72.6M
– –
-478,827
Closed -$7.66M
TEX icon
413
Terex
TEX
$7.23B
– –
-4,934
Closed -$292K
TRX icon
414
TRX Gold Corp
TRX
$377M
– –
-630,174
Closed -$945K
URI icon
415
United Rentals
URI
$62.9B
– –
-385
Closed -$280K
VRAX icon
416
Virax Biolabs
VRAX
$2.1M
– –
-35,152
Closed -$193K
VSXY
417
Victoria's Secret
VSXY
$6.01B
– –
-55,693
Closed -$2.58M
VVOS icon
418
Vivos Therapeutics
VVOS
$3.75M
– –
-1,115,859
Closed -$1.32M
WKSP icon
419
Worksport
WKSP
$8.57M
– –
-250,195
Closed -$263K
WLDS icon
420
Wearable Devices
WLDS
$4.5M
– –
-76,917
Closed -$332K
WWW icon
421
Wolverine World Wide
WWW
$1.7B
– –
-125,000
Closed -$2.04M
XLE icon
422
State Street Energy Select Sector SPDR ETF
XLE
$41.7B
– –
-13,114
Closed -$803K
XLU icon
423
State Street Utilities Select Sector SPDR ETF
XLU
$22.2B
– –
-6,077
Closed -$279K
XOP icon
424
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
$4.06B
– –
-2,733
Closed -$497K
AS icon
425
Amer Sports
AS
$17.2B
– –
-148,770
Closed -$4.9M
14 15 16
17
18

Similar funds

MWM
Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return
SC
Saturna Capital Bellingham, Washington $8.19B AUM 42.01% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
BIM
Bridges Investment Management Omaha, Nebraska $8.22B AUM 21.38% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Armistice Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Armistice Capital held 432 positions worth $8.17B, up 45% from $5.62B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Armistice Capital's Q2 2026 filing shows 171 new, 73 increased, 69 reduced and 99 closed positions. Its largest new stake was Waters Corp: 75,004 shares worth $28.1M. The largest sale was Travere Therapeutics, an estimated $147M.

By sector, the portfolio is most concentrated in Miscellaneous at 56% of assets, up from 46% a quarter earlier, followed by Healthcare and Technology.

  • Armistice Capital's largest Q2 2026 buy was Waters Corp: 75,004 shares worth $28.1M.
  • Armistice Capital added most to Regeneron Pharmaceuticals in Q2 2026, an estimated $36.5M increase.
  • Armistice Capital's biggest Q2 2026 reduction was Travere Therapeutics, cutting an estimated $147M.
  • Armistice Capital fully exited Avanos Medical in Q2 2026, selling an estimated $28M.
  • Armistice Capital's ten largest holdings make up 62% of its $8.17B portfolio in Q2 2026.
  • Armistice Capital opened 171 new positions and closed 99 in Q2 2026.
  • Armistice Capital's portfolio value rose 45% quarter-over-quarter to $8.17B.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.